Singleron Biotechnologies

Singleron Biotechnologies specializes in end-to-end single-cell sequencing solutions, offering a comprehensive suite of products including kits, instruments, and bioinformatics tools. Their innovative technology empowers clinical researchers to translate complex disease insights into actionable medical guidance, advancing precision medicine. The company serves a global clientele, including research institutions and pharmaceutical companies, by providing high-quality data generation and advanced bioinformatics interpretation. With a commitment to advancing precision medicine, Singleron has successfully processed over a billion sequenced single cells across various applications in oncology, immunology, and neurosciences. The company operates with an employee range of 500 - 1,000 individuals, contributing to its extensive research and development capabilities. Meet Singleron Biotechnologies' team to learn more about their dedicated personnel driving innovation in the biotech sector. Their strategic focus on high-throughput sequencing and data analysis positions them at the forefront of genomic research and drug development. Singleron Biotechnologies has secured significant funding, including a $30 million round in December 2020, underscoring investor confidence in their technology and market potential. Explore financial highlights for detailed insights into their fiscal performance and growth trajectory. The company's B2B model and focus on critical research areas highlight its role in the broader healthcare ecosystem.